Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

Hope S. Rugo*, Seock Ah Im, Fatima Cardoso, Javier Cortés, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Gail S. Wright, Cristina Saura, Santiago Escrivá-De-Romaní, Michelino De Laurentiis, Christelle Levy, Ursa Brown-Glaberman, Jean Marc Ferrero, Maaike De Boer, Sung Bae Kim, Katarína Petráková, Denise A. Yardley, Orit Freedman, Erik H. JakobsenBella Kaufman, Rinat Yerushalmi, Peter A. Fasching, Jeffrey L. Nordstrom, Ezio Bonvini, Scott Koenig, Sutton Edlich, Shengyan Hong, Edwin P. Rock, William J. Gradishar

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

247 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology